2023 World Conference on Lung Cancer (Posters)-P2.12. Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations

P2.12. Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations - PDF(Slides)

Back to course

Pdf Summary

This study focused on the clinical and molecular features of advanced non-small cell lung cancer (NSCLC) with leptomeningeal metastases (LM) and uncommon genetic drivers. The researchers identified patients with NSCLC who had uncommon oncogenic alterations, such as atypical EGFR mutations, ROS1/RET fusions, and ERBB2 alteration. They analyzed the clinical outcomes and compared the molecular features of these patients with those who had classical EGFR mutations. <br /><br />The results showed that patients with LM and atypical EGFR mutations or ROS1/RET fusions had improved prognoses compared to those with ERBB2-positive LM. The genomic landscape of atypical EGFR mutations was found to be similar to classical EGFR mutations. Patients with fusions had the longest median overall survival (27.8 months), followed by those with atypical EGFR mutations (8 months) and ERBB2 mutations (4.8 months). The overall survival for patients with ROS1 fusion was longer than those with RET fusion.<br /><br />The researchers also collected cerebrospinal fluids from patients with molecular profiles. They found co-mutations, including TP53, MYC, CDK4, and CDKN2A, in the atypical EGFR mutation group. These co-mutation profiles were similar to those with classical EGFR mutations.<br /><br />Overall, the study highlights the importance of targeted therapies for patients with LM and uncommon genetic drivers. Patients with atypical EGFR mutations or ROS1/RET fusions have better prognoses compared to those with ERBB2-positive LM. The findings contribute to the understanding of the molecular characteristics of NSCLC with LM and uncommon genetic drivers.

Asset Subtitle

Guang-Ling Jie

Meta Tag

Speaker Guang-Ling Jie

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

non-small cell lung cancer

leptomeningeal metastases

uncommon genetic drivers

atypical EGFR mutations

ROS1/RET fusions

ERBB2 alteration

clinical outcomes

molecular features

genomic landscape

overall survival